Updated Jul 16, 2026
Versant Venture Capital VI, L.P. is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $54.41M.

| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-09-30 | LENZ | LENZ Therapeutics, Inc. | S — Open-market sale | 123 | $47.01 | $6K |
| 2025-09-30 | LENZ | LENZ Therapeutics, Inc. | S — Open-market sale | 177 | $47.01 | $8K |
| 2025-09-30 | LENZ | LENZ Therapeutics, Inc. | S — Open-market sale | 57.5K | $46.41 | $2.67M |
| 2025-09-30 | LENZ | LENZ Therapeutics, Inc. | S — Open-market sale | 83.1K | $46.41 | $3.85M |
| 2025-09-30 | LENZ | LENZ Therapeutics, Inc. | S — Open-market sale | 34.4K | $45.35 | $1.56M |
| 2025-09-30 | LENZ | LENZ Therapeutics, Inc. | S — Open-market sale | 49.7K | $45.35 | $2.25M |
| 2025-09-19 | LVTX | LAVA Therapeutics NV | S — Open-market sale | 532.9K | $1.40 | $747K |
| 2025-09-19 | LVTX | LAVA Therapeutics NV | S — Open-market sale | 2.37M | $1.40 | $3.32M |
| 2025-09-18 | LENZ | LENZ Therapeutics, Inc. | S — Open-market sale | 132 | $43.30 | $6K |
| 2025-09-18 | LENZ | LENZ Therapeutics, Inc. | S — Open-market sale | 268 | $43.30 | $12K |
| 2025-09-18 | LENZ | LENZ Therapeutics, Inc. | S — Open-market sale | 20.1K | $43.00 | $866K |
| 2025-09-18 | LENZ | LENZ Therapeutics, Inc. | S — Open-market sale | 40.9K | $43.00 | $1.76M |
| 2025-09-18 | LENZ | LENZ Therapeutics, Inc. | S — Open-market sale | 24.4K | $41.59 | $1.01M |
| 2025-09-18 | LENZ | LENZ Therapeutics, Inc. | S — Open-market sale | 49.5K | $41.59 | $2.06M |
| 2025-09-16 | LVTX | LAVA Therapeutics NV | S — Open-market sale | 228.8K | $1.44 | $330K |
| 2025-09-16 | LVTX | LAVA Therapeutics NV | S — Open-market sale | 366.1K | $1.44 | $528K |
| 2025-09-16 | LVTX | LAVA Therapeutics NV | S — Open-market sale | 226.7K | $1.49 | $338K |
| 2025-09-16 | LVTX | LAVA Therapeutics NV | S — Open-market sale | 362.8K | $1.49 | $540K |
| 2025-09-16 | LVTX | LAVA Therapeutics NV | S — Open-market sale | 192.3K | $1.53 | $295K |
| 2025-09-16 | LVTX | LAVA Therapeutics NV | S — Open-market sale | 307.7K | $1.53 | $472K |
Versant Venture Capital VI, L.P. is a corporate insider — currently tracked as Insider. InsiderAlpha tracks every SEC Form 4 filing in real time.
Recorded transactions: 0 open-market purchases () and 41 open-market sales ($54.41M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Versant Venture Capital VI, L.P. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.